New names given nonalcoholic fatty liver diseases fit children: Study
Almost every child and adolescent who met diagnostic criteria for forms of nonalcoholic fatty liver disease under their previous names — NAFL, NASH, or…
Fatty liver disease
Semaglutide shows liver benefits in Phase 3 MASH trial
Weekly injections of semaglutide, a medication sold in the U.S. under brand names including Ozempic and Wegovy to treat type 2 diabetes and obesity, reduced…
Fatty liver disease affects 45% of teens, adults in US, Hispanics most
About 45% of teens and adults in the U.S. have some form of fatty liver disease, with Hispanic populations being more affected than other…
Sagimet planning Phase 3 trials of denifanstat in MASH, MASLD
Sagimet Biosciences is planning the launch of two Phase 3 clinical trials to test its oral therapy candidate denifanstat in people with fatty…
Study fully enrolled of Rezdiffra for well-compensated liver cirrhosis
A Phase 3 clinical trial testing Rezdiffra (resmetirom) in people with well-compensated cirrhosis, or irreversible liver scarring that still allows the liver to work, due…
Therapy to silence SPTBN1 protein eases liver fat, scarring in mice
Suppressing the production of the SPTBN1 protein reduces liver fat, inflammation, and scarring (fibrosis) in mouse and human models of two forms of fatty…
Survodutide wins breakthrough therapy for fatty liver disease
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy status to survodutide, an experimental injectable therapy by Boehringer Ingelheim for metabolic dysfunction-associated steatohepatitis…
FDA gives denifanstat for MASH breakthrough therapy status
The U.S. Food and Drug Administration (FDA) has given breakthrough therapy designation to denifanstat, Sagimet Biosciences’ investigational oral therapy for metabolic dysfunction-associated steatohepatitis…
Lanifibranor may be reason for liver gains seen in Phase 3 MASH trial
Signs of improved liver health are evident in biomarker and liver scarring assessments of people with metabolic-associated steatohepatitis or MASH — a severe form of…
Potential THR-beta agonist may more safely, effectively treat MASH
Once daily treatment with oral ALG-055009 safely lowered levels of liver fat in people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty…
Recent Posts
- Telehealth program helps improve hepatitis C treatment in rural US
- PBC therapy Ocaliva pulled from EU market with court decision
- Study: New ABCB4 mutations tied to different ages of PFIC3 onset
- Our son with Alagille syndrome is finding it hard to fall asleep
- New names given nonalcoholic fatty liver diseases fit children: Study